sur Xenetic Biosciences, Inc. (NASDAQ:XBIO)
Xenetic Biosciences' Abstract Accepted for Presentation at SITC 2024
Xenetic Biosciences, Inc. (NASDAQ: XBIO), a biopharmaceutical company, announced that its abstract has been selected for poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, Texas. The conference will take place from November 6-10, 2024, with both in-person and virtual attendance options available.
The presentation, titled "DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint Blockade in Models of MSS/MMRp CRC," will be delivered by Dr. Reid Bissonnette. It will be held on November 8, 2024, from 9:00 a.m. to 7:00 p.m. CST at the George R. Brown Convention Center.
Xenetic focuses on innovative immuno-oncology technologies, utilizing its DNase platform to improve cancer treatment outcomes by targeting neutrophil extracellular traps. Their current efforts are directed towards advancing their systemic DNase program as an adjunctive therapy for challenging oncology indications.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Xenetic Biosciences, Inc.